{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:07:49Z","timestamp":1790024869885,"version":"4.0.1"},"reference-count":168,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Federal Ministry of Education and Research (BMBF)","award":["e:Med-MelAutim 01ZX1905B"],"award-info":[{"award-number":["e:Med-MelAutim 01ZX1905B"]}]},{"name":"German Federal Ministry of Education and Research (BMBF)","award":["e:Med-MelAutim 01ZX1905D"],"award-info":[{"award-number":["e:Med-MelAutim 01ZX1905D"]}]},{"name":"German Federal Ministry of Education and Research (BMBF)","award":["70112353"],"award-info":[{"award-number":["70112353"]}]},{"name":"German Federal Ministry of Education and Research (BMBF)","award":["PU 188\/17-1"],"award-info":[{"award-number":["PU 188\/17-1"]}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid (Deutsche Krebshilfe)","doi-asserted-by":"publisher","award":["e:Med-MelAutim 01ZX1905B"],"award-info":[{"award-number":["e:Med-MelAutim 01ZX1905B"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid (Deutsche Krebshilfe)","doi-asserted-by":"publisher","award":["e:Med-MelAutim 01ZX1905D"],"award-info":[{"award-number":["e:Med-MelAutim 01ZX1905D"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid (Deutsche Krebshilfe)","doi-asserted-by":"publisher","award":["70112353"],"award-info":[{"award-number":["70112353"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid (Deutsche Krebshilfe)","doi-asserted-by":"publisher","award":["PU 188\/17-1"],"award-info":[{"award-number":["PU 188\/17-1"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation (DFG)","doi-asserted-by":"publisher","award":["e:Med-MelAutim 01ZX1905B"],"award-info":[{"award-number":["e:Med-MelAutim 01ZX1905B"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation (DFG)","doi-asserted-by":"publisher","award":["e:Med-MelAutim 01ZX1905D"],"award-info":[{"award-number":["e:Med-MelAutim 01ZX1905D"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation (DFG)","doi-asserted-by":"publisher","award":["70112353"],"award-info":[{"award-number":["70112353"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation (DFG)","doi-asserted-by":"publisher","award":["PU 188\/17-1"],"award-info":[{"award-number":["PU 188\/17-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Cancer cells have a remarkable ability to evade recognition and destruction by the immune system. At the same time, cancer has been associated with chronic inflammation, while certain autoimmune diseases predispose to the development of neoplasia. Although cancer immunotherapy has revolutionized antitumor treatment, immune-related toxicities and adverse events detract from the clinical utility of even the most advanced drugs, especially in patients with both, metastatic cancer and pre-existing autoimmune diseases. Here, the combination of multi-omics, data-driven computational approaches with the application of network concepts enables in-depth analyses of the dynamic links between cancer, autoimmune diseases, and drugs. In this review, we focus on molecular and epigenetic metastasis-related processes within cancer cells and the immune microenvironment. With melanoma as a model, we uncover vulnerabilities for drug development to control cancer progression and immune responses. Thereby, drug repurposing allows taking advantage of existing safety profiles and established pharmacokinetic properties of approved agents. These procedures promise faster access and optimal management for cancer treatment. Together, these approaches provide new disease-based and data-driven opportunities for the prediction and application of targeted and clinically used drugs at the interface of immune-mediated diseases and cancer towards next-generation immunotherapies.<\/jats:p>","DOI":"10.3390\/pharmaceutics15010083","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T08:42:22Z","timestamp":1672216942000},"page":"83","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease"],"prefix":"10.3390","volume":"15","author":[{"given":"Alf","family":"Spitschak","sequence":"first","affiliation":[{"name":"Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-3260","authenticated-orcid":false,"given":"Shailendra","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Systems Biology and Bioinformatics, University of Rostock, 18057 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Systems Biology and Bioinformatics, University of Rostock, 18057 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Logotheti","sequence":"additional","affiliation":[{"name":"Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte M.","family":"P\u00fctzer","sequence":"additional","affiliation":[{"name":"Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057 Rostock, Germany"},{"name":"Department Life, Light & Matter, University of Rostock, 18059 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ccell.2019.12.004","article-title":"Cancer Genome Evolutionary Trajectories in Metastasis","volume":"37","author":"Birkbak","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/jnci\/djp458","article-title":"E2F1 in melanoma progression and metastasis","volume":"102","author":"Alla","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1586\/era.10.153","article-title":"Predicting and preventing melanoma invasiveness: Advances in clarifying E2F1 function","volume":"10","author":"Steder","year":"2010","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/onc.2013.540","article-title":"HER2\/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors","volume":"34","author":"Andrechek","year":"2015","journal-title":"Oncogene"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2009.25.0977","article-title":"Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors","volume":"28","author":"Lee","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41467-017-00268-2","article-title":"Unraveling a tumor type-specific regulatory core underlying E2F1-mediated epithelial-mesenchymal transition to predict receptor protein signatures","volume":"8","author":"Khan","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1158\/0008-5472.CAN-12-4095","article-title":"Kinetic modeling-based detection of genetic signatures that provide chemoresistance via the E2F1-p73\/DNp73-miR-205 network","volume":"73","author":"Vera","year":"2013","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/nar\/gkv885","article-title":"Epigenetic factor EPC1 is a master regulator of DNA damage response by interacting with E2F1 to silence death and activate metastasis-related gene signatures","volume":"44","author":"Wang","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/jmcb\/mjt035","article-title":"E2F1 promotes angiogenesis through the VEGF-C\/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B","volume":"5","author":"Engelmann","year":"2013","journal-title":"J. Mol. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/path.4400","article-title":"Association of RHAMM with E2F1 promotes tumour cell extravasation by transcriptional up-regulation of fibronectin","volume":"234","author":"Meier","year":"2014","journal-title":"J. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.15252\/embr.201439392","article-title":"E2F1 induces miR-224\/452 expression to drive EMT through TXNIP downregulation","volume":"15","author":"Knoll","year":"2014","journal-title":"EMBO Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9620","DOI":"10.7150\/thno.44176","article-title":"LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1","volume":"10","author":"Logotheti","year":"2020","journal-title":"Theranostics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13046-019-1286-9","article-title":"Rewiring E2F1 with classical NHEJ via APLF suppression promotes bladder cancer invasiveness","volume":"38","author":"Richter","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.semcancer.2018.06.006","article-title":"Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis","volume":"53","author":"Marquardt","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.7150\/thno.29546","article-title":"Drug Repositioning Inferred from E2F1-Coregulator Interactions Studies for the Prevention and Treatment of Metastatic Cancers","volume":"9","author":"Goody","year":"2019","journal-title":"Theranostics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.biocel.2012.12.021","article-title":"Nodal signalling in embryogenesis and tumourigenesis","volume":"45","author":"Quail","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"20395","DOI":"10.18632\/oncotarget.7954","article-title":"CWP232228 targets liver cancer stem cells through Wnt\/\u03b2-catenin signaling: A novel therapeutic approach for liver cancer treatment","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jneuroim.2017.12.016","article-title":"Crosstalk between cancer and the neuro-immune system","volume":"315","author":"Kuol","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13046-018-0674-x","article-title":"Role of the nervous system in cancer metastasis","volume":"37","author":"Kuol","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4049\/jimmunol.1900828","article-title":"The Neuroimmune Axis in the Tumor Microenvironment","volume":"204","author":"Shurin","year":"2020","journal-title":"J. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/1878-0261.12741","article-title":"Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution","volume":"14","author":"Dora","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Logotheti, S., and P\u00fctzer, B.M. (2019). STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases. Cancers, 11.","DOI":"10.3390\/cancers11101448"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1073\/pnas.94.20.10889","article-title":"Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression","volume":"94","author":"Hitt","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/jnci\/93.6.472","article-title":"Large nontransplanted hepatocellular carcinoma in woodchucks: Treatment with adenovirus-mediated delivery of interleukin 12\/B7.1 genes","volume":"93","author":"Stiewe","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e20201979","DOI":"10.1084\/jem.20201979","article-title":"Immune checkpoint inhibitors","volume":"218","author":"Kroemer","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40425-017-0283-9","article-title":"The immune system in cancer metastasis: Friend or foe?","volume":"5","author":"Janssen","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: Impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"868695","DOI":"10.3389\/fphar.2022.868695","article-title":"The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment","volume":"13","author":"Kim","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_32","first-page":"375","article-title":"Cancer Immunotherapy, Part 1: Current Strategies and Agents","volume":"42","author":"Ventola","year":"2017","journal-title":"Pharm. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ma, Q., Shilkrut, M., Zhao, Z., Li, M., Batty, N., and Barber, B. (2018). Autoimmune comorbidities in patients with metastatic melanoma: A retrospective analysis of us claims data. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4051-0"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: The first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"ref_35","first-page":"1","article-title":"Future prospects of immune checkpoint blockade in cancer: From response prediction to overcoming resistance","volume":"50","author":"Park","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1172\/JCI90499","article-title":"Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer","volume":"127","author":"Taylor","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1158\/0008-5472.CAN-16-0194","article-title":"Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/nyas.13625","article-title":"Regulatory T cells: A potential target in cancer immunotherapy","volume":"1417","author":"Shitara","year":"2018","journal-title":"Ann. New York Acad. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fonc.2019.00279","article-title":"Turning the Tide Against Regulatory T Cells","volume":"9","author":"Han","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","article-title":"Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity","volume":"23","author":"Wang","year":"2018","journal-title":"Cell Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","article-title":"Antiangiogenic therapy in oncology: Current status and future directions","volume":"388","author":"Jayson","year":"2016","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fonc.2014.00070","article-title":"Control of the immune response by pro-angiogenic factors","volume":"4","author":"Voron","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients with Melanoma Treated with Ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab Therapy in Patients with Advanced Melanoma and Preexisting Autoimmune Disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2006.02.016","article-title":"Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer","volume":"124","author":"Karin","year":"2006","journal-title":"Cell"},{"key":"ref_51","first-page":"41","article-title":"Cancer, comorbidities, and health-related quality of life of older adults","volume":"29","author":"Smith","year":"2008","journal-title":"Health Care Financ. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"737","DOI":"10.18632\/oncotarget.624","article-title":"Infection, inflammation and colon carcinogenesis","volume":"3","author":"Wogan","year":"2012","journal-title":"Oncotarget"},{"key":"ref_53","first-page":"1119","article-title":"Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer","volume":"32","author":"Franks","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"854967","DOI":"10.3389\/fphar.2022.854967","article-title":"PD-1\/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1476-4598-12-98","article-title":"Cancer risk in immune-mediated inflammatory diseases (IMID)","volume":"12","author":"Beyaert","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pharmthera.2015.06.011","article-title":"The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where","volume":"154","author":"Pateras","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2011-01-325266","article-title":"Autoimmunity associated with immunotherapy of cancer","volume":"118","author":"Amos","year":"2011","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jaut.2014.05.002","article-title":"Activation of benign autoimmunity as both tumor and autoimmune disease immunotherapy: A comprehensive review","volume":"54","author":"Cohen","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjd.12111","article-title":"Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: A survey among 1307 patients and their partners","volume":"168","author":"Teulings","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: A systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"178","DOI":"10.5021\/ad.2009.21.2.178","article-title":"Vitiligo-like Depigmentation Associated with Metastatic Melanoma of an Unknown Origin","volume":"21","author":"Cho","year":"2009","journal-title":"Ann. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.canlet.2018.11.009","article-title":"DNp73-induced degradation of tyrosinase links depigmentation with EMT-driven melanoma progression","volume":"442","author":"Steder","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.it.2016.03.009","article-title":"Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis","volume":"37","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/ced.12531","article-title":"Association between autoimmune disease and cutaneous melanoma with regard to melanoma prognosis","volume":"40","author":"Bottoni","year":"2015","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4161\/mabs.27333","article-title":"Antibodies to watch in 2014","volume":"6","author":"Reichert","year":"2014","journal-title":"MAbs"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/19420862.2015.988944","article-title":"Antibodies to watch in 2015","volume":"7","author":"Reichert","year":"2015","journal-title":"MAbs"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/19420862.2015.1125583","article-title":"Antibodies to watch in 2016","volume":"8","author":"Reichert","year":"2016","journal-title":"MAbs"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/19420862.2016.1269580","article-title":"Antibodies to watch in 2017","volume":"9","author":"Reichert","year":"2017","journal-title":"MAbs"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/19420862.2018.1415671","article-title":"Antibodies to watch in 2018","volume":"10","author":"Kaplon","year":"2018","journal-title":"MAbs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1703531","DOI":"10.1080\/19420862.2019.1703531","article-title":"Antibodies to watch in 2020","volume":"12","author":"Kaplon","year":"2020","journal-title":"MAbs"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1860476","DOI":"10.1080\/19420862.2020.1860476","article-title":"Antibodies to watch in 2021","volume":"13","author":"Kaplon","year":"2021","journal-title":"MAbs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri2761","article-title":"Therapeutic antibodies for autoimmunity and inflammation","volume":"10","author":"Chan","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3229","article-title":"Development trends for human monoclonal antibody therapeutics","volume":"9","author":"Nelson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/intimm\/dxu096","article-title":"Therapeutic uses of anti-\u03b14-integrin (anti-VLA-4) antibodies in multiple sclerosis","volume":"27","author":"Schwab","year":"2015","journal-title":"Int. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/cam4.1098","article-title":"Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)","volume":"6","author":"Sabol","year":"2017","journal-title":"Cancer Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2147\/TCRM.S143509","article-title":"Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: Perspectives from the Alemtuzumab Clinical Development Program","volume":"13","author":"Havrdova","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2147\/TCRM.S134398","article-title":"Alemtuzumab: A review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis","volume":"13","author":"Guarnera","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: A meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"h2809","DOI":"10.1136\/bmj.h2809","article-title":"Association between tumour necrosis factor-\u03b1 inhibitors and risk of serious infections in people with inflammatory bowel disease: Nationwide Danish cohort study","volume":"350","author":"Pasternak","year":"2015","journal-title":"BMJ"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.3748\/wjg.v20.i19.5912","article-title":"TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: A case report and literature review","volume":"20","author":"Usha","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_83","first-page":"281","article-title":"Cutaneous side effects of TNF-alpha inhibitors","volume":"15","author":"Lindhaus","year":"2017","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.autrev.2017.07.022","article-title":"Cancer and autoimmune diseases","volume":"16","author":"Giat","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: A comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"750","DOI":"10.6004\/jnccn.2019.7310","article-title":"Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors","volume":"17","author":"Kennedy","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of Programmed Death-1 Pathway Inhibitors Among Patients with Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e000538","DOI":"10.1136\/jitc-2020-000538","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: A retrospective international multicenter study","volume":"8","author":"Xie","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e002121","DOI":"10.1136\/jitc-2020-002121","article-title":"Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders","volume":"9","author":"Brown","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/M20-3419","article-title":"Safety and Efficacy of Checkpoint Inhibition in Patients with Melanoma and Preexisting Autoimmune Disease: A Cohort Study","volume":"174","author":"Suijkerbuijk","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1126\/science.287.5460.1969","article-title":"Mechanism-based target identification and drug discovery in cancer research","volume":"287","author":"Gibbs","year":"2000","journal-title":"Science"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.drudis.2011.12.008","article-title":"What makes a good drug target?","volume":"17","author":"Gashaw","year":"2012","journal-title":"Drug Discov. Today"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"175031","DOI":"10.1016\/j.ejphar.2022.175031","article-title":"Drug repurposing: An emerging strategy in alleviating skin cancer","volume":"926","author":"Kumbhar","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","article-title":"The updated landscape of tumor microenvironment and drug repurposing","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2174\/1874467215666220214104530","article-title":"Drug Repurposing for Cancer Therapy in the Era of Precision Medicine","volume":"15","author":"To","year":"2022","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-020-00213-8","article-title":"Overcoming cancer therapeutic bottleneck by drug repurposing","volume":"5","author":"Zhang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3892\/ol.2021.12927","article-title":"Anthelminthic niclosamide inhibits tumor growth and invasion in cisplatin-resistant human epidermal growth factor receptor 2-positive breast cancer","volume":"22","author":"Liu","year":"2021","journal-title":"Oncol. Lett."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/tox.22551","article-title":"Niclosamide, an oral antihelmintic drug, exhibits antimetastatic activity in hepatocellular carcinoma cells through downregulating twist-mediated CD10 expression","volume":"33","author":"Chien","year":"2018","journal-title":"Environ. Toxicol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"113610","DOI":"10.1016\/j.bcp.2019.08.012","article-title":"Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway","volume":"169","author":"Zhu","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s40425-019-0733-7","article-title":"Niclosamide, an antihelmintic drug, enhances efficacy of PD-1\/PD-L1 immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Luo","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Burock, S., Daum, S., Keilholz, U., Neumann, K., Walther, W., and Stein, U. (2018). Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: The NIKOLO trial. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4197-9"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.4049\/jimmunol.1900594","article-title":"Cutting Edge: Targeting Thrombocytes to Rewire Anticancer Immunity in the Tumor Microenvironment and Potentiate Efficacy of PD-1 Blockade","volume":"203","author":"Riesenberg","year":"2019","journal-title":"J. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/bloodadvances.2018026161","article-title":"Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis","volume":"3","author":"Johnson","year":"2019","journal-title":"Blood Adv."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1073\/pnas.1804000116","article-title":"Aspirin-triggered proresolving mediators stimulate resolution in cancer","volume":"116","author":"Gilligan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"De Jaeghere, E.A., Tuyaerts, S., van Nuffel, A.M.T., Belmans, A., Bogaerts, K., Baiden-Amissah, R., Lippens, L., Vuylsteke, P., Henry, S., and Trinh, X.B. (2022). Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study. Cancer Immunol. Immunother., 1\u20137.","DOI":"10.1007\/s00262-022-03253-x"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-011-0749-z","article-title":"RANKL\/RANK-beyond bones","volume":"89","author":"Hanada","year":"2011","journal-title":"J. Mol. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s12094-018-02023-5","article-title":"The RANK-RANKL axis: An opportunity for drug repurposing in cancer?","volume":"21","author":"Peters","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"key":"ref_114","first-page":"1039","article-title":"Anti-tumor role of metformin","volume":"19","author":"Dempsey","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/2326-6066.CIR-16-0103","article-title":"Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia","volume":"5","author":"Scharping","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00428-018-2445-7","article-title":"Predictive potential and need for standardization of PD-L1 immunohistochemistry","volume":"474","author":"Bubendorf","year":"2019","journal-title":"Virchows Arch."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"117923","DOI":"10.1016\/j.lfs.2020.117923","article-title":"Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer","volume":"256","author":"Shen","year":"2020","journal-title":"Life Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","article-title":"Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1","volume":"71","author":"Cha","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"586760","DOI":"10.3389\/fimmu.2020.586760","article-title":"Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/annonc\/mdh300","article-title":"Thalidomide in cancer medicine","volume":"15","author":"Bamias","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Rauf, A., Abu-Izneid, T., Khalil, A.A., Imran, M., Shah, Z.A., Emran, T.B., Mitra, S., Khan, Z., Alhumaydhi, F.A., and Aljohani, A.S.M. (2021). Berberine as a Potential Anticancer Agent: A Comprehensive Review. Molecules, 26.","DOI":"10.3390\/molecules26237368"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Liu, X., Ji, Q., Ye, N., Sui, H., Zhou, L., Zhu, H., Fan, Z., Cai, J., and Li, Q. (2015). Berberine Inhibits Invasion and Metastasis of Colorectal Cancer Cells via COX-2\/PGE2 Mediated JAK2\/STAT3 Signaling Pathway. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0123478"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.phymed.2016.12.013","article-title":"Berberine inhibits the proliferation and migration of breast cancer ZR-75-30 cells by targeting Ephrin-B2","volume":"25","author":"Ma","year":"2017","journal-title":"Phytomedicine"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bcp.2011.11.008","article-title":"Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression","volume":"83","author":"Kim","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Liu, J.-F., Lai, K.C., Peng, S.-F., Maraming, P., Huang, Y.-P., Huang, A.-C., Chueh, F.-S., Huang, W.-W., and Chung, J.-G. (2018). Berberine Inhibits Human Melanoma A375.S2 Cell Migration and Invasion via Affecting the FAK, uPA, and NF-\u03baB Signaling Pathways and Inhibits PLX4032 Resistant A375.S2 Cell Migration In Vitro. Molecules, 23.","DOI":"10.3390\/molecules23082019"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Tsang, C.M., Cheung, Y.C., Lui, V.W.-Y., Yip, Y.L., Zhang, G., Lin, V.W., Cheung, K.C.-P., Feng, Y., and Tsao, S.W. (2013). Berberine suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor associated fibroblasts. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-619"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1759720X20969261","DOI":"10.1177\/1759720X20969261","article-title":"Shared development of targeted therapies among autoimmune and inflammatory diseases: A systematic repurposing analysis","volume":"12","author":"Petitdemange","year":"2020","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41584-019-0337-0","article-title":"Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases","volume":"16","author":"Kingsmore","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature12873","article-title":"Genetics of rheumatoid arthritis contributes to biology and drug discovery","volume":"506","author":"Okada","year":"2014","journal-title":"Nature"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1177\/1352458520928301","article-title":"Gut commensals, dysbiosis, and immune response imbalance in the pathogenesis of multiple sclerosis","volume":"27","author":"Brown","year":"2021","journal-title":"Mult. Scler."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/WCO.0000000000000818","article-title":"Mechanisms underlying progression in multiple sclerosis","volume":"33","author":"Absinta","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Amadio, S., Conte, F., Esposito, G., Fiscon, G., Paci, P., and Volont\u00e9, C. (2022). Repurposing Histaminergic Drugs in Multiple Sclerosis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116347"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"860726","DOI":"10.3389\/fimmu.2022.860726","article-title":"Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs","volume":"13","author":"Garantziotis","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_135","first-page":"1662","article-title":"Type I interferon-mediated autoimmune diseases: Pathogenesis, diagnosis and targeted therapy","volume":"56","author":"Psarras","year":"2017","journal-title":"Rheumatology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"102429","DOI":"10.1016\/j.autrev.2019.102429","article-title":"Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies","volume":"19","author":"Puig","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"Plenge","year":"2012","journal-title":"Immunity"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-4939-8955-3_2","article-title":"Performing an In Silico Repurposing of Existing Drugs by Combining Virtual Screening and Molecular Dynamics Simulation","volume":"1903","author":"Sohraby","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/onc.2017.328","article-title":"Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment","volume":"37","author":"Nagaraj","year":"2018","journal-title":"Oncogene"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The Drug Repurposing Hub: A next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.chembiol.2017.11.009","article-title":"Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions","volume":"25","author":"Tang","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.drudis.2017.09.007","article-title":"Uncovering novel repositioning opportunities using the Open Targets platform","volume":"22","author":"Khaladkar","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"170029","DOI":"10.1038\/sdata.2017.29","article-title":"A standard database for drug repositioning","volume":"4","author":"Brown","year":"2017","journal-title":"Sci. Data"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","article-title":"ZINC 15--Ligand Discovery for Everyone","volume":"55","author":"Sterling","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/bib\/bbw136","article-title":"Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning","volume":"19","author":"Shameer","year":"2018","journal-title":"Brief. Bioinform."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1093\/bioinformatics\/btz302","article-title":"ClinOmicsTrailbc: A visual analytics tool for breast cancer treatment stratification","volume":"35","author":"Schneider","year":"2019","journal-title":"Bioinformatics"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41746-022-00617-6","article-title":"Computational drug repurposing based on electronic health records: A scoping review","volume":"5","author":"Zong","year":"2022","journal-title":"NPJ Digit. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12539-021-00487-8","article-title":"Machine Learning Applications in Drug Repurposing","volume":"14","author":"Yang","year":"2022","journal-title":"Interdiscip. Sci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/17460441.2021.1883585","article-title":"Artificial intelligence, machine learning, and drug repurposing in cancer","volume":"16","author":"Tanoli","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.semcancer.2019.12.011","article-title":"Machine and deep learning approaches for cancer drug repurposing","volume":"68","author":"Issa","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/omi.2019.0151","article-title":"Rethinking Drug Repositioning and Development with Artificial Intelligence, Machine Learning, and Omics","volume":"23","author":"Koromina","year":"2019","journal-title":"OMICS"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/23808993.2018.1424535","article-title":"Drug repositioning: Current approaches and their implications in the precision medicine era","volume":"3","author":"Talevi","year":"2018","journal-title":"Expert Rev. Precis. Med. Drug Dev."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1758-2946-5-30","article-title":"Drug repositioning: A machine-learning approach through data integration","volume":"5","author":"Napolitano","year":"2013","journal-title":"J. Cheminform."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1021\/jm010548w","article-title":"Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B","volume":"45","author":"Doman","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/2040622313494987","article-title":"Argatroban in heparin-induced thrombocytopenia: Rationale for use and place in therapy","volume":"4","author":"Bambrah","year":"2013","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_156","first-page":"105","article-title":"The direct thrombin inhibitor argatroban: A review of its use in patients with and without HIT","volume":"1","author":"Koster","year":"2007","journal-title":"Biologics"},{"key":"ref_157","unstructured":"Mercader, A.G., Duchowicz, P.R., and Sivakumar, P.M. (2021). Chemometrics Applications and Research: QSAR in Medicinal Chemistry, Apple Academic Press."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Gupta, V.K., and Tuohy, M.G. (2015). Virtual screening and prediction of the molecular mechanism of bioactive compounds in silico. Biotechnology of Bioactive Compounds, John Wiley & Sons, Ltd.","DOI":"10.1002\/9781118733103"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/0929867043456287","article-title":"Predicting molecular interactions in silico: I. A guide to pharmacophore identification and its applications to drug design","volume":"11","author":"Dror","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1021\/ci300083r","article-title":"Protein-ligand-based pharmacophores: Generation and utility assessment in computational ligand profiling","volume":"52","author":"Meslamani","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4155\/fmc.13.204","article-title":"Structure-based design of small-molecule protein-protein interaction modulators: The story so far","volume":"6","author":"Falchi","year":"2014","journal-title":"Future Med. Chem."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/prot.21702","article-title":"Template-based modeling and free modeling by I-TASSER in CASP7","volume":"69","author":"Zhang","year":"2007","journal-title":"Proteins"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Zhang, Y. (2008). I-TASSER server for protein 3D structure prediction. BMC Bioinform., 9.","DOI":"10.1186\/1471-2105-9-40"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nprot.2010.5","article-title":"I-TASSER: A unified platform for automated protein structure and function prediction","volume":"5","author":"Roy","year":"2010","journal-title":"Nat. Protoc."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/protein\/gzm083","article-title":"LOOPER: A molecular mechanics-based algorithm for protein loop prediction","volume":"21","author":"Spassov","year":"2008","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1110\/ps.062447107","article-title":"The dominant role of side-chain backbone interactions in structural realization of amino acid code. ChiRotor: A side-chain prediction algorithm based on side-chain backbone interactions","volume":"16","author":"Spassov","year":"2007","journal-title":"Protein Sci."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/prot.10389","article-title":"ZDOCK: An initial-stage protein-docking algorithm","volume":"52","author":"Chen","year":"2003","journal-title":"Proteins"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/prot.10460","article-title":"RDOCK: Refinement of rigid-body protein docking predictions","volume":"53","author":"Li","year":"2003","journal-title":"Proteins"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/1\/83\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:52:26Z","timestamp":1760147546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/1\/83"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":168,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["pharmaceutics15010083"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15010083","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]}}}